Ozempic vs Wegovy: The Same Drug Under Different Names

The short answer

Ozempic and Wegovy are both semaglutide, a GLP-1 receptor agonist developed and manufactured by Novo Nordisk. The active molecule is identical. The differences are regulatory and operational, not pharmacological.

• Ozempic — FDA-approved 2017 for type 2 diabetes; subsequently approved for cardiovascular risk reduction in T2D with CV disease. Maximum dose: 2 mg weekly.
• Wegovy — FDA-approved 2021 for chronic weight management in adults with obesity or overweight with weight-related comorbidities. Maximum dose: 2.4 mg weekly.

Same molecule, same injection pen design, same once-weekly subcutaneous route, same overall mechanism. The 0.4 mg dose difference at maximum and the indication difference are the only meaningful distinctions.

Why two brands for one drug

The pattern is common in pharmaceuticals. Reasons:

Indication-specific FDA approvals. Drugs are approved for specific indications, not generically. Approving semaglutide for diabetes is a separate regulatory process from approving it for obesity — separate Phase 3 trials, separate label, separate brand identity.

Distinct dose ranges. Diabetes management typically uses 0.5-2 mg weekly. Obesity management benefits from higher doses (1.7-2.4 mg). Distinct brands allow distinct prescribing information.

Payer separation. Insurance coverage operates on indication-specific approvals. Diabetes medications often have more generous coverage than obesity medications. Different brands maintain different coverage policies.

Marketing focus. Diabetes-focused marketing emphasizes glycemic control and CV benefits. Obesity-focused marketing emphasizes weight loss magnitude. Separate brands enable targeted communication.

Practical differences that matter

Dose ceiling: Wegovy goes to 2.4 mg weekly; Ozempic caps at 2 mg. For patients seeking maximum weight-loss magnitude, Wegovy's higher dose is the meaningful operational difference.

Insurance coverage: Often the biggest practical issue. A plan may cover Ozempic for diabetes generously while restricting Wegovy for obesity. Patients with T2D may have easier coverage paths to Ozempic.

Prior authorization: Step therapy and PA requirements often differ between the brands even though the medication is the same.

Pharmacy stocking: Patterns of availability differ. Some pharmacies stock one but not the other depending on local prescribing patterns.

Manufacturer programs: Coupons and savings programs are separate for each brand. Eligibility for one doesn't transfer.

Off-label use of Ozempic for weight loss

Common but technically outside the FDA approval. Patients without diabetes who use Ozempic for weight loss are using it off-label; the appropriate FDA-indicated path for non-diabetic weight loss is Wegovy. Clinically, the effects are the same molecule producing the same effects; regulatorily, the indication matters for insurance and prescribing context.

During the 2022-2024 shortage period, off-label Ozempic use for weight loss expanded substantially because Wegovy was less consistently available. Post-shortage, the landscape has normalized somewhat.

What the SELECT trial means for both

The SELECT trial (2023) demonstrated 20% reduction in major adverse cardiovascular events with semaglutide 2.4 mg weekly in adults with overweight/obesity and established cardiovascular disease. The trial used the dose corresponding to Wegovy's maximum dose. This led to expanded labeling for Wegovy specifically for cardiovascular risk reduction in obesity-CVD patients — a relatively unique distinction in the obesity medication space.

For patients with obesity and established cardiovascular disease, the SELECT data favors Wegovy specifically. For patients with diabetes (regardless of CVD), Ozempic has the longer evidence base (SUSTAIN-6 in 2016) and FDA cardiovascular indication.